Clinical trial
Effect of Casodex on Tumour Hypoxia - Prostate Cancer
NCT00188708 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00188708 |
|---|---|
| Title | Effect of Casodex on Tumour Hypoxia - Prostate Cancer |
| Official title | A Study of the Effect of Neoadjuvant Bicalutamide (Casodex) on Tumour Hypoxia in Patients With Clinically Localized Prostate Cancer |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | Canadian Cancer Trials Group Princess Margaret Hospital, Canada |
| Status | Completed |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Procedure |
| Interventions | hypoxia measurement |
| Enrollment | 30 |
| Start date | Apr 1, 2001 |
| Primary completion | Mar 10, 2022 |
| Completion | Mar 10, 2022 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 18, 2024 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: